



2012). Dalším tématem je využití antidepresiv v rámci prevence deprese. Jako nejúčinnější se jeví podání amiptryptilinu (Burch, 2019).

## Závěr

Tento článek se zabývá jen zlomkem neurologických a psychiatrických poruch. Vzájemnost obou skupin je mnohem širší. Navzdory

vysoké frekvenci existuje jen málo informací o etiopatogenezi psychických poruch u neurologických pacientů. Stejně tak doposud neexistuje dostatečné množství kvalitních, placebem kontrolovaných farmakologických studií, které by umožňovalo dát jednoznačná terapeutická doporučení a hlavně vytvořit specifický přístup pro tuto skupinu pacientů.

## LITERATURA

1. Aarsland D, Pålhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease – epidemiology, mechanisms and management. *Nature Reviews Neurology* 2012; 8(1): 35.
2. Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC, Buse DC. Depression and risk of transformation of episodic to chronic migraine. *The journal of headache and pain* 2012; 13(8): 615–624.
3. Ayerbe L, Ayis S, Crichton SL, Rudd AG, Wolfe CD. Explanatory factors for the increased mortality of stroke patients with depression. *Neurology* 2014; 83: 2007–2012.
4. Baskin SM, Smitherman TA. Comorbidity between migraine and depression: update on traditional and alternative treatments. *Neurol Sci* 2011; 32(Suppl. 1): 9–13.
5. Boeschoten RE, Braamse AMJ, Beekman ATF, Cuijpers P, van Oppen P, Dekker J, Uitendaele BMJ. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. *J. Neurol. Sci* 2017; 372: 331–341.
6. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KMA. Comorbidity of migraine and depression: investigating potential etiology and prognosis. *Neurology* 2003; 60(8): 1308–1312.
7. Brown RG, Jahanshahi M, Marsden CD. Response choice in Parkinson's disease: the effects of uncertainty and stimulus-response compatibility. *Brain* 1993; 4: 869–885.
8. Brown RG, Marsden CD, Quinn N, Wyke MA. Alterations in cognitive performance and effect-arousal during fluctuations in motor function in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1984; 47: 454–465.
9. Burch R. Antidepressants for preventive treatment of migraine. *Current treatment options in neurology* 2019; 21(4): 18.
10. Bužgová R, Hajnová E, Feltl D, Stolička M. Faktory ovlivňující úzkost a depresi u pacientů v konečném stadiu nemoci při hospitalizaci. *česká a slovenská Psychiatrie* 2014; 110(5): 243–249.
11. Feinstein A, Roy P, Lobaugh N, Feinstein K, O'Connor P, Black S. Structural brain abnormalities in multiple sclerosis patients with major depression. *Neurology* 2004; 62: 586–590.
12. Fiest KM, Walker JR, Bernstein CN, Graff LA, Zarychanski R, Abou-Setta AM, Fisk JD. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. *Multiple sclerosis and related disorders* 2016; 5: 12–26.
13. Fredrikson S, Cheng Q, Jiang GX, Wasserman D. Elevated suicide risk among patients with multiple sclerosis in Sweden. *Neuroepidemiology* 2003; 22(2): 146–152.
14. Global Parkinson's Disease Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. *Mov Disord* 2002; 17: 60–67.
15. Hackett ML, Anderson CS. Predictors of depression after stroke: a systematic review of observational studies. *Stroke* 2005; 36(10): 2296–2301.
16. Hackett ML, Anderson CS, House A, Xla J. Interventions for treating depression after stroke. *Cochrane Database Syst Rev* 2008; (4): CD003437.
17. Hamelsky SW, Lipton RB. Psychiatric comorbidity of migraine. *Headache: The Journal of Head and Face Pain* 2006; 46(9): 1327–1333.
18. Herrmann N, Black SE, Lawrence J, Szekely C, Szalai JP. Sunnybrook Stroke Study: a prospective study of depressive symptoms and functional outcome. *Stroke* 1998; 29: 618–62.
19. Hung CI, Wang SJ, Yang CH, Liu CY. The impacts of migraine, anxiety disorders, and chronic depression on quality of life in psychiatric outpatients with major depressive disorder. *J Psychosom Res* 2008; 65(2): 135–142.
20. Mills KA, Greene MC, Dezube R, Goodson C, Karmarkar T, Pontone GM. Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis. *International journal of geriatric psychiatry* 2018; 33(4): 642–651.
21. Mitchell PH, Veith RC, Becker KJ, Buzaitis A, Cain KC, Fruin M, Teri L. Brief psychosocial-behavioral intervention with antidepressant reduces poststroke depression significantly more than usual care with antidepressant: living well with stroke: randomized, controlled trial. *Stroke* 2009; 40(9): 3073–3078.